Findings

What do systematic reviews say?

4,703 questions · 15,007 findings · 1,416 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,881 · 19.2%GRADE not reported 1,551 · 10.3%Very low 3,111 · 20.7%Low 3,881 · 25.9%Moderate 2,669 · 17.8%High 914 · 6.1%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Recombinant human C1 esterase inhibitor vs placebo or active control

Disability (any validated scale) (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Recombinant human C1 esterase inhibitor vs placebo or active control

Adverse events(during · children or adults with Types I or II HAE

Recombinant human C1 esterase inhibitor showed no clear difference in adverse events(during compared with placebo or active control (low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 1.39 [0.71, 2.7]
1 study · 29 participants
Low

Lanadelumab vs placebo or active control

Risk of HAE attacks (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Lanadelumab vs placebo or active control

Change in number of HAE attacks (per week) · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 83 participants
Low

Lanadelumab vs placebo or active control

Mortality (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Lanadelumab vs placebo or active control

Serious adverse events (during · children or adults with Types I or II HAE

Lanadelumab showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 0.88 [0.08, 10.39]
2 studies · 162 participants
Low

Lanadelumab vs placebo or active control

Differences in quality of life ( · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 68 participants
Low

Lanadelumab vs placebo or active control

Disability standardised mean difference (lower is better) (during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 64 participants
Low

Lanadelumab vs placebo or active control

Adverse events(during · children or adults with Types I or II HAE

Lanadelumab showed no clear difference in adverse events(during compared with placebo or active control (low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 1.07 [0.77, 1.47]
2 studies · 158 participants
Low

Avoralstat vs placebo

Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 93 participants
Moderate

Avoralstat vs placebo

Disability (any validated scale) (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Avoralstat vs placebo

Adverse events (during · children or adults with Types I or II HAE

Avoralstat showed no clear difference in adverse events (during compared with placebo (low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 0.85 [0.62, 1.16]
1 study · 24 participants
Low

Berotralstat vs placebo or active control

Risk of HAE attacks (during · children or adults with Types I or II HAE

Berotralstat showed no clear difference in risk of HAE attacks (during compared with placebo or active control (low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 0.63 [0.39, 1]
1 study · 37 participants
Low

Berotralstat vs placebo or active control

Change in number of HAE attacks (per week) · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 130 participants
Low

Zinc oxide mesh vs placebo mesh

Proportion of wounds healed · adults with open wounds after surgery for sacrococcygeal pilonidal sinus disease

The review found no eligible studies for this question.

3 findings from 1 review

Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal pilonidal… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal pilonidal… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal pilonidal… 2022 · Cochrane Headline outcomes only
RR 2.35 [0.49, 11.23]
1 study · 64 participants
Very low

Zinc oxide mesh vs placebo mesh

Cost‐effectiveness · adults with open wounds after surgery for sacrococcygeal pilonidal sinus disease

The review found no eligible studies for this question.

1 finding from 1 review

Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal pilonidal… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Zinc oxide mesh vs placebo mesh

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · adults with open wounds after surgery for sacrococcygeal pilonidal sinus disease

The review found no eligible studies for this question.

1 finding from 1 review

Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal pilonidal… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Zinc oxide mesh vs placebo mesh

Adverse effects (surgical site infection or allergic reaction) · adults with open wounds after surgery for sacrococcygeal pilonidal sinus disease

1 finding from 1 review

Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal pilonidal… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 64 participants
GRADE not reported

Zinc oxide mesh vs placebo mesh

Time to complete healing · adults with open wounds after surgery for sacrococcygeal pilonidal sinus disease

1 finding from 1 review

Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal pilonidal… 2022 · Cochrane Headline outcomes only
no estimate extracted
54 participants
Low

Hydrocortisone vs placebo

Severity of PTSD symptoms · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found